Physician profile
Aju Daniel
NPI 1962652560
$4,609.52
in general payments reported to CMS, 2019-2025
27 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,452 · 2020: $377 · 2021: $132 · 2022: $364 · 2023: $368 · 2024: $594 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $752.57 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $717.14 | 2019-2025 | Dovato, Apretude |
| Novo Nordisk INC | $416.46 | 2019-2025 | Wegovy, Ozempic |
| Janssen Products, Lp | $324.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $322.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $253.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.62 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $178.48 | 2019-2024 | |
| Allergan, INC. | $157.50 | 2019 | |
| Paratek Pharmaceuticals, INC. | $154.21 | 2021-2022 | |
| Amarin Pharma, INC. | $144.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.22 | 2019-2022 | |
| Mylan Specialty L.P. | $113.99 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $110.34 | 2019-2024 | Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $110.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $104.60 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $87.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $66.59 | 2019 | |
| Melinta Therapeutics, LLC | $48.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $38.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.31 | 2019 | |
| Alkermes, INC. | $30.97 | 2023 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $25.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.04 | 2020 | |
| Napo Pharmaceuticals INC | $12.67 | 2019 | |
| Phathom Pharmaceuticals, INC. | $5.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aju Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.